Back to Encyclopedia

Testagen

Bioregulators

Also known as: Testes Bioregulator, Testagen Khavinson Peptide

Half-life: Short (minutes); biological effect persists via gene-expression modulation

Last reviewed:  ·  Published:

Anti AgingSexual Health

Overview

Testagen is a short peptide bioregulator from the Khavinson family, designed for testicular and male reproductive applications. It is proposed to target testicular Leydig cell and Sertoli cell gene expression to support testosterone production, spermatogenesis, and overall reproductive health in men. The compound has been used in Russian clinical settings for age-related testosterone decline, infertility evaluation, and recovery from testicular damage.

Russian clinical-observational studies have reported improvements in serum testosterone levels, sperm parameters, and subjective measures of vitality in elderly men and in male infertility populations. The mechanism is presumed to involve modulation of testicular gene expression via the broader Khavinson short-peptide bioregulator pathway, supporting Leydig-cell testosterone synthesis and Sertoli-cell support of spermatogenesis.

Testagen is sold by research-chemical vendors outside Russia. Western clinical data is essentially absent. The compound should not be used as a substitute for evaluation and management of hypogonadism by an endocrinologist or as a substitute for established fertility therapies. Self-experimentation in men with significant fertility concerns is not a substitute for proper clinical evaluation.

History

Testagen was developed in the 2000s as part of the Khavinson bioregulator program, with the testicular-targeting member of the family aimed at age-related testosterone decline, male infertility, and recovery from testicular injury. The compound entered Russian clinical observational use through the 2000s and 2010s.

Effects

  • Reported support of Leydig cell testosterone production
  • Possible improvement in sperm parameters
  • Support of overall reproductive function
  • Anti-inflammatory effects in testicular tissue
  • Modulation of testicular gene expression

Side Effects

  • Generally well-tolerated in Russian clinical use
  • Mild injection-site reactions
  • Limited Western safety validation
  • Should not substitute for proper hypogonadism evaluation

Tolerability

Russian clinical use has reported good tolerability in male reproductive-health populations. Western safety validation is essentially absent. Men with significant hypogonadism or fertility concerns should undergo proper endocrinological evaluation before relying on any peptide bioregulator — the diagnostic distinction between primary testicular failure, secondary (hypothalamic-pituitary) hypogonadism, and age-related decline matters for treatment selection.

Dosing Ranges

Reproductive support

Dose Range

1-5 mg

Frequency

Once daily (SubQ) or sublingual

Duration

10-20 day cycles, repeated 2-3 times per year

Dosing information is for educational purposes only. Consult a healthcare professional before using any peptide.

Reconstitution

Preparation Details

Typical Vial Size

20 mg

Water Type

Bacteriostatic water (BAC water)

Mixing Volume

2 mL

Half-Life

Short (minutes); biological effect persists via gene-expression modulation

Molecular Weight

~400-600 Da

Store reconstituted vial refrigerated at 2-8°C. Use within 21-30 days. Sublingual or subcutaneous administration is typical.

Calculate Testagen dose

Regulatory Status

FDA Status

Not FDA approved.

Legal Status

Unregulated research chemical outside Russia.

USA

Not approved

Research-only

EU

Not approved

Not authorized as medicinal product

UK

Not approved

Classified as research chemical

Russia

Used in clinical practice

Used as bioregulator in Russian endocrinology and reproductive medicine

Australia

Not approved

TGA has not evaluated

Canada

Not approved

Not authorized for human use

Cited Studies

Peptide regulation of aging: 35 years of research experience

Khavinson VK, Kuznik BI, Tarnovskaya SI, Linkova NS

Bulletin of Experimental Biology and Medicine (2015)

Foundational Khavinson-group review covering the full short-peptide bioregulator family including Testagen.

View Study →

Mechanisms of biological action of short peptides: the role of cell genome regulation

Khavinson VK, Anisimov VN, Linkova NS, Bakhmet AA

Bulletin of Experimental Biology and Medicine (2020)

Modern Khavinson-group mechanistic review applicable to all tissue-targeting bioregulators including Testagen.

View Study →

Peptide bioregulators in endocrinology: 30 years of clinical experience

Khavinson VK, Kuznik BI, Linkova NS

Advances in Gerontology (2019)

Russian-group review of peptide bioregulators in endocrinological applications including Testagen and the broader testicular-support context.

View Study →

Compare Testagen with

Track Testagen and more with PinnyPeptide.

Sign Up to Track Testagen

Free forever · defaults pre-filled from this article